🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07414082
Starting soon Not applicable

Serum Talin-1 and Cripto-1 in Colorectal Cancer

NCT07414082 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-03-30
Last updated
2026-02-17

Condition(s) studied

Colo-rectal Cancer

Investigational drug(s) / intervention(s)

Serum level of Human Talin-1Serum level of Human Cripto-1

Serum level of Human Talin-1: To evaluate the clinical utility of Talin-1 measurement in colorectal cancer patients in comparison with healthy controls.

Serum level of Human Cripto-1: To evaluate the clinical utility of Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.

Study summary

The goals of this study are

* To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
* To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age \>18 years Old. * Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction) * Patients diagnosed with colorectal cancer by imaging and histopathology Exclusion Criteria: * Age \<18 years old. * Patients with past history of chemotherapy or surgical excision of tumor * Patients with familial adenomatous polyposis * Patients with hereditary non-polyposis colorectal cancer * Patients with inflammatory bowel disease * patients with other types of tumors

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Assuit University Hospital Asyut Asyut Governorate

More Assiut University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07414082 on ClinicalTrials.gov ↗ ← All trials in Egypt